Nama's AI scorecard currently rates Progyny Buy (7.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PGNY's P/E ratio?

Progyny trades at a trailing price-to-earnings ratio of 17.0.

When does PGNY report earnings?

Progyny's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.54.

What is the PGNY price target?

The median analyst price target from 12 analysts is $35.00, with a range of $30.00 – $40.00.

Is PGNY Shariah compliant?

Nama's AAOIFI-style screen reads Progyny as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Progyny (PGNY)

Healthcare · Healthcare Plans · NASDAQ

Progyny (PGNY) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $2.58B, a trailing price-to-earnings ratio of 17.0 and a free-cash-flow yield of 6.1%. Over the most recent reported fiscal year, revenue grew 10.4% and free cash flow per share grew 17.3%. Nama's AI scorecard rates it Buy, 7.9 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.9/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +53.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-48.9%

How far the last close sits under the highest price of the past five years.

Market cap	$2.58B
Trailing P/E	17.0
Price / book	6.0
Price / sales	2.0
FCF yield	6.1%
Dividend yield	—
Gross margin	24.6%
Operating margin	8.6%
Net margin	6.0%
Revenue growth (YoY)	+10.4%
Revenue growth (3-yr annual)	+17.9%
EPS growth (YoY)	+15.2%
FCF/share growth (YoY)	+17.3%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Healthcare Plans

PGNY earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.54). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.52	$0.51	+2.0%	—
Q2 2026	Aug 6, 2026	$0.55	$0.53	+3.8%	$350.51M
Q1 2026	May 7, 2026	$0.50	$0.44	+13.6%	$328.50M
Q4 2025	Feb 26, 2026	$0.48	$0.40	+20.0%	$318.40M

PGNY analyst price target

Median target $35.00 from 12 analysts, ranging $30.00 – $40.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
ELV	Elevance Health	$91.96B	14.0
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
CNC	Centene	$34.53B	13.2
MOH	Molina Healthcare	$10.87B	104.5
OSCR	Oscar Health	$9.46B	12.7

Explore live PGNY data on Nama Insights →

Recent Congressional trades

Progyny trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jan 14, 2025

PGNY FAQ

Is PGNY a buy?: Nama's AI scorecard currently rates Progyny Buy (7.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PGNY's P/E ratio?: Progyny trades at a trailing price-to-earnings ratio of 17.0.
When does PGNY report earnings?: Progyny's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.54.
What is the PGNY price target?: The median analyst price target from 12 analysts is $35.00, with a range of $30.00 – $40.00.
Is PGNY Shariah compliant?: Nama's AAOIFI-style screen reads Progyny as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.